Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

Several other research firms have also commented on HUMA. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

NASDAQ HUMA opened at $3.40 on Wednesday. Humacyte has a one year low of $2.81 and a one year high of $9.97. The company has a 50-day simple moving average of $4.36 and a 200-day simple moving average of $4.96. The firm has a market capitalization of $427.92 million, a PE ratio of -2.54 and a beta of 1.30.

Hedge Funds Weigh In On Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after buying an additional 543,995 shares in the last quarter. State Street Corp grew its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Woodline Partners LP grew its holdings in Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after buying an additional 2,000,268 shares in the last quarter. Geode Capital Management LLC grew its holdings in Humacyte by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock worth $10,785,000 after buying an additional 94,915 shares in the last quarter. Finally, CenterBook Partners LP bought a new position in Humacyte in the 4th quarter worth approximately $6,463,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.